Capecitabine combined with weekly docetaxel in Chinese patients > 65 years with anthracycline-resistant metastatic breast cancer
文献类型：期刊论文
| 刊名 | CHINESE MEDICAL JOURNAL
 |
| 出版日期 | 2010 |
| 卷号 | 123 |
| 关键词 | PHASE-III TRIAL PLUS DOCETAXEL MULTICENTER THERAPY PHOSPHORYLASE TOLERABILITY PACLITAXEL XELODA(R) SURVIVAL capecitabine weekly docetaxel metastatic breast cancer anthracycline elderly tolerability |
| ISSN号 | 0366-6999 |
| 其他题名 | Capecitabine combined with weekly docetaxel in Chinese patients >65 years with anthracycline-resistant metastatic breast cancer |
| 英文摘要 | Background There are no data on more tolerable capecitabine doses in elderly patients in Chinese population The aim of this study was to evaluate the activity and safety of capecitabine combined with weekly docetaxel for the treatment of anthracycline-resistant metastatic breast cancer (MBC) in older Chinese patients |
| 语种 | 英语 |
| CSCD记录号 | CSCD:4044437 |
| 源URL | [http://ir.hfcas.ac.cn:8080/handle/334002/61872]  |
| 专题 | 中国科学院合肥物质科学研究院 |
| 推荐引用方式 GB/T 7714 | . Capecitabine combined with weekly docetaxel in Chinese patients > 65 years with anthracycline-resistant metastatic breast cancer[J]. CHINESE MEDICAL JOURNAL,2010,123. |
| APA | (2010).Capecitabine combined with weekly docetaxel in Chinese patients > 65 years with anthracycline-resistant metastatic breast cancer.CHINESE MEDICAL JOURNAL,123. |
| MLA | "Capecitabine combined with weekly docetaxel in Chinese patients > 65 years with anthracycline-resistant metastatic breast cancer".CHINESE MEDICAL JOURNAL 123(2010). |
入库方式： OAI收割
来源：合肥物质科学研究院
浏览0
下载0
收藏0
其他版本
除非特别说明，本系统中所有内容都受版权保护，并保留所有权利。